The stock of Clovis Oncology Inc (NASDAQ:CLVS) is a huge mover today! About 8.98 million shares traded hands or 123.94% up from the average. Clovis Oncology Inc (NASDAQ:CLVS) has risen 65.76% since March 4, 2016 and is uptrending. It has outperformed by 57.72% the S&P500.
The move comes after 7 months negative chart setup for the $1.12B company. It was reported on Oct, 7 by Barchart.com. We have $28.60 PT which if reached, will make NASDAQ:CLVS worth $67.20M less.
Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on November, 3. They expect $-1.93 EPS, up 26.34% or $0.69 from last year’s $-2.62 per share. After $-2.07 actual EPS reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts -6.76% EPS growth.
Clovis Oncology Inc (NASDAQ:CLVS) Ratings Coverage
Out of 8 analysts covering Clovis Oncology (NASDAQ:CLVS), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. Clovis Oncology has been the topic of 23 analyst reports since September 10, 2015 according to StockzIntelligence Inc. Piper Jaffray reinitiated the stock with “Neutral” rating in Monday, April 4 report. Piper Jaffray maintained Clovis Oncology Inc (NASDAQ:CLVS) on Monday, November 16 with “Neutral” rating. As per Wednesday, August 24, the company rating was maintained by Mizuho. The company was maintained on Monday, January 25 by Mizuho. The firm has “Neutral” rating given on Monday, November 16 by Mizuho. WallachBeth Capital maintained it with “Buy” rating and $134 target price in Thursday, September 10 report. The stock has “Outperform” rating given by Credit Suisse on Thursday, January 21. WallachBeth Capital maintained Clovis Oncology Inc (NASDAQ:CLVS) on Monday, May 9 with “Hold” rating. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has “Buy” rating given on Friday, February 26 by Stifel Nicolaus. The stock of Clovis Oncology Inc (NASDAQ:CLVS) earned “Buy” rating by Suntrust Robinson on Wednesday, August 24.
According to Zacks Investment Research, “Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.13, from 0.87 in 2016Q1. The ratio is positive, as 36 funds sold all Clovis Oncology Inc shares owned while 26 reduced positions. 18 funds bought stakes while 44 increased positions. They now own 36.50 million shares or 0.57% less from 36.71 million shares in 2016Q1.
State Bank Of America Corporation De holds 0% or 7,240 shares in its portfolio. Atwood Palmer Inc holds 100 shares or 0% of its portfolio. Apriem Advisors holds 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 400 shares. California Pub Employees Retirement holds 0% or 26,700 shares in its portfolio. Moreover, Creative Planning has 0% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 1,864 shares. Antipodean Advsrs Limited Liability holds 4.34% or 523,000 shares in its portfolio. Barclays Public Limited Co holds 0% or 24,178 shares in its portfolio. The Germany-based Deutsche National Bank Ag has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Centurylink Management holds 0.02% or 3,256 shares in its portfolio. Blackrock Institutional Trust Co Na reported 823,036 shares or 0% of all its holdings. State Street Corporation has 1.64 million shares for 0% of their US portfolio. Putnam Ltd holds 52,467 shares or 0% of its portfolio. Moreover, Tower Rech Ltd Liability (Trc) has 0.01% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 7,105 shares. D E Shaw accumulated 593,481 shares or 0.02% of the stock. Profund Advsr Limited Liability Company holds 0.01% or 19,227 shares in its portfolio.
More notable recent Clovis Oncology Inc (NASDAQ:CLVS) news were published by: Benzinga.com which released: “Clovis Oncology Tumbles 20% On Rucaparib Data” on October 07, 2016, also Fool.com with their article: “Why Clovis Oncology Inc. Is Soaring Today” published on September 08, 2016, Streetinsider.com published: “Clovis Oncology (CLVS), Lonza Enter into Manufacturing Services Agreement for …” on October 04, 2016. More interesting news about Clovis Oncology Inc (NASDAQ:CLVS) were released by: Fool.com and their article: “Is Clovis Oncology Still a Strong Buy?” published on September 12, 2016 as well as Investorplace.com‘s news article titled: “Why Clovis Oncology Inc (CLVS), Philip Morris International Inc. (PM) And …” with publication date: September 22, 2016.
CLVS Company Profile
Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.